Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk

Дата публикации: 30-09-2026 22:10:18

New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased cardiovascular risk, a daily orforglipron pill had cardiovascular safety comparable to daily insulin glargine injections while providing greater improvements in weight and blood sugar control. However, gastrointestinal (GI) adverse events were more common with orforglipron, leading to more treatment discontinuations. The study was sponsored by Eli Lilly, the manufacturer of orforglipron.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages	0	7.03	26-09-2026
2	Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests	0	7.86	27-09-2026
3	Continuous glucose monitoring may lower mortality risk in diabetic patients on insulin	0	9.69	27-09-2026
4	Diyabet ve obezite ilacında yeni keşif: 'Yaşam süresini ve kalitesini artırabilir'	0	7.43	16-09-2026
5	Almost 1 in 3 adults develop cardiorenal disease or die within 5 years of type 2 diabetes diagnosis	0	11.25	01-10-2026
6	Двойной эффект. Как препараты для снижения веса и сахара защищают сердце	0	6.47	01-10-2026
7	Un nou medicament promite scădere spectaculoasă în greutate pentru persoanele cu diabet de tip 2	0	6.32	30-09-2026
8	EU launches first Screening Week to help detect heart and diabetes risks earlier	0	3.91	29-09-2026
9	New evidence supports possible anticancer effects with GLP-1s	0	9.55	18-09-2026
10	Blood pressure medication recalled nationwide under FDA's Class II risk level	0	6.6	28-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.3. Источник: medicalxpress.com.